Related Experiment Video
Updated: Jun 15, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Evaluation of S-1 as third- or further-line chemotherapy in advanced non-small-cell lung cancer
Akira Ono1, Tateaki Naito, Haruyasu Murakami
1Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Background:
No investigation of S-1 monotherapy in previously treated advanced non-small-cell lung cancer (NSCLC) patients has yet been reported. We conducted a retrospective study to evaluate the efficacy and tolerability of S-1 in patients with failure of second- or further-line chemotherapy.
Patients And Methods:
The records of NSCLC patients who had received S-1 monotherapy between January 2005 and November 2006 with the following eligibility criteria were reviewed: previously treated with at least two regimens including platinum and docetaxel in the case of nonadenocarcinoma patients, and including platinum, docetaxel and epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) in the case of adenocarcinoma patients. S-1 was administered for 28 consecutive days, followed by a 14-day drug-free period (42 days in one course). The drug was administered in two divided doses daily at 80 mg/day for patients with a body surface area <1.25 m(2), 100 mg/day for those with a body surface area of 1.25-1.5 m(2), and 120 mg/day for those with a body surface area > or = 1.5 m(2).
Results:
Thirty-five patients were registered. The median number of courses administered per patient was 2 (range 1-9). The toxicity profile was mild, and grade 3 or more severe toxicity was rare. The overall response and disease control rates were 5.7% and 40%, respectively. The median survival time was 208 days.
Conclusion:
S-1 exhibits modest activity and acceptable toxicity when used as a third or subsequent line of chemotherapy in patients with advanced NSCLC.
Insights
S-1 monotherapy showed modest efficacy and acceptable toxicity in previously treated advanced non-small-cell lung cancer (NSCLC) patients. This study evaluated S-1 as a third or subsequent line of chemotherapy for advanced NSCLC.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Limited data exists on S-1 monotherapy for previously treated advanced non-small-cell lung cancer (NSCLC).
- This retrospective study addresses the efficacy and tolerability of S-1 in patients who failed second- or further-line chemotherapy.
Purpose of the Study:
- To evaluate the efficacy and tolerability of S-1 monotherapy.
- To assess S-1 as a third or subsequent line of chemotherapy in advanced NSCLC.
Main Methods:
- Retrospective review of 35 advanced NSCLC patients treated with S-1 monotherapy (Jan 2005-Nov 2006).
- Patients had prior treatment with platinum, docetaxel, and EGFR-TKIs (for adenocarcinoma).
- S-1 was administered on a 28-day on, 14-day off schedule with dose adjustments based on body surface area.
Main Results:
- Median of 2 courses administered per patient.
- Mild toxicity profile with rare severe adverse events (grade 3+).
- Overall response rate of 5.7% and disease control rate of 40%; median survival time of 208 days.
Conclusions:
- S-1 monotherapy demonstrates modest activity in advanced NSCLC.
- S-1 is well-tolerated as a third or subsequent line of therapy for advanced NSCLC.
- Further investigation into S-1 for advanced NSCLC is warranted.
